Stock listing

OTC:NWBO Northwest Biotherapeutics, Inc. Stock

Follow Northwest Biotherapeutics, Inc. into a list and get an email when it puts out news.

Share price · OTC:NWBO

$0.129 USD -0.016 (-11.1%)

Close on Nov 20, 2026

Past year -46.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.122 – $0.139 USDNov 20, 2026
Volume
2.29M sharesNov 20, 2026
Market cap
$220.0M USDAt the close on Nov 20, 2026 · price × 1.71B shares outstanding
52-week range
$0.122 – $0.340 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$630,668 USDMedian day 2.65M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Northwest Biotherapeutics, Inc. logo

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:NWBO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.129-0.016-11.1%$0.135$0.139$0.1222,291,092
$0.145-0.002-1.3%$0.153$0.157$0.1451,266,072
$0.147+0.001+0.5%$0.148$0.153$0.1383,462,853
$0.146-0.009-5.9%$0.155$0.155$0.1451,503,737
$0.155-0.012-7.4%$0.166$0.166$0.1552,336,022
$0.168-0.001-0.4%$0.170$0.171$0.1641,257,156
$0.168+0.001+0.8%$0.168$0.168$0.164739,706
$0.167+0.001+0.7%$0.168$0.168$0.166723,190
$0.166-0.001-0.6%$0.169$0.169$0.1632,160,055
$0.167+0.002+1.3%$0.169$0.170$0.1631,917,976
$0.1650.000-0.1%$0.170$0.171$0.1603,631,484
$0.165-0.003-1.8%$0.169$0.185$0.1574,273,163
$0.168-0.008-4.5%$0.175$0.176$0.168887,107
$0.176+0.006+3.5%$0.170$0.177$0.160658,946
$0.1700.0000.0%$0.170$0.180$0.1703,044,800
$0.1700.0000.0%$0.170$0.170$0.1703,931,900
$0.170+0.010+6.3%$0.160$0.170$0.1602,277,600
$0.160-0.010-5.9%$0.170$0.170$0.1605,861,900
$0.170+0.020+13.3%$0.150$0.170$0.1507,525,400
$0.1500.0000.0%$0.150$0.160$0.1505,487,100
$0.150-0.020-11.8%$0.170$0.170$0.1504,593,600
$0.170+0.010+6.3%$0.160$0.170$0.1606,510,200
$0.1600.0000.0%$0.160$0.170$0.1505,902,200
$0.1600.0000.0%$0.160$0.160$0.1504,291,500
$0.160+0.010+6.7%$0.160$0.160$0.1503,915,700
$0.150-0.010-6.3%$0.160$0.170$0.1504,430,800
$0.1600.0000.0%$0.170$0.170$0.1605,334,800
$0.1600.0000.0%$0.160$0.170$0.1606,752,500
$0.1600.0000.0%$0.170$0.180$0.16018,208,100
$0.160+0.010+6.7%$0.160$0.170$0.15019,062,800
$0.1500.0000.0%$0.150$0.160$0.1405,582,200
$0.1500.0000.0%$0.140$0.150$0.1403,906,300
$0.1500.0000.0%$0.150$0.150$0.1403,909,900
$0.1500.0000.0%$0.150$0.150$0.1402,499,100
$0.1500.0000.0%$0.150$0.160$0.1501,512,800
$0.1500.0000.0%$0.140$0.150$0.1401,537,900
$0.1500.0000.0%$0.150$0.150$0.1403,438,300
$0.1500.0000.0%$0.150$0.160$0.1504,896,500
$0.150-0.010-6.3%$0.160$0.160$0.1503,918,100
$0.1600.0000.0%$0.160$0.160$0.1602,348,200
$0.1600.0000.0%$0.160$0.170$0.1602,391,500
$0.1600.0000.0%$0.160$0.160$0.1602,443,600
$0.160-0.010-5.9%$0.170$0.170$0.1602,778,200
$0.170+0.010+6.3%$0.160$0.170$0.1604,581,300
$0.160-0.010-5.9%$0.170$0.170$0.1604,589,700
$0.1700.0000.0%$0.170$0.170$0.1601,260,900
$0.1700.0000.0%$0.170$0.180$0.1601,941,500
$0.170+0.010+6.3%$0.170$0.170$0.1701,814,900
$0.160-0.010-5.9%$0.170$0.170$0.1601,449,800
$0.1700.0000.0%$0.170$0.170$0.1601,207,100
$0.1700.0000.0%$0.170$0.170$0.170880,600
$0.1700.0000.0%$0.180$0.180$0.1702,650,300
$0.1700.0000.0%$0.170$0.170$0.1702,608,600
$0.1700.0000.0%$0.170$0.170$0.1701,722,700
$0.1700.0000.0%$0.170$0.170$0.1701,452,700
$0.1700.0000.0%$0.170$0.170$0.1603,331,500
$0.1700.0000.0%$0.170$0.170$0.1702,049,000
$0.170-0.020-10.5%$0.190$0.200$0.17018,376,200
$0.190+0.010+5.6%$0.180$0.230$0.18010,430,800
$0.180+0.010+5.9%$0.170$0.180$0.1702,417,600
$0.170-0.004-2.2%$0.170$0.180$0.1701,262,400
$0.174+0.001+0.8%$0.175$0.175$0.1661,936,134
$0.173+0.002+1.5%$0.170$0.177$0.1665,231,098
$0.1700.0000.0%$0.170$0.180$0.1603,194,500
$0.170-0.010-5.6%$0.180$0.180$0.1702,217,000

Splits

2 splits since 2007 · OTC:NWBO · every price before a split is adjusted for it

DayRatioWhat
1-for-16Consolidation
1-for-15Consolidation
Ticker
OTC:NWBO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Northwest Biotherapeutics, Inc. news

Northwest Biotherapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 3 in all · newest Oct 26, 2026 · oldest 2026
Decks
15 decks · latest Jul 3, 2026

Valuation

EV/sales 99.4× against a median of 1.3×: 4th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$283.8M USD
P/E
Loss
EV/sales
99.4×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
0.90

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Northwest Biotherapeutics, Inc. · OTC:NWBOUS$220.0MUS$283.8Mn/a99.4×n/an/an/an/a0.90
Enanta Pharmaceuticals, Inc. · NASDAQ:ENTAUS$222.2MUS$82.43Mn/a1.3×n/a2.8×−108.3%0.7×1.11
Clover Biopharmaceuticals Ltd. · HKEX:2197US$222.0MUS$206.5Mn/a403×n/an/an/an/an/a
Aprilbio Co., Ltd. · KRX:397030US$221.1MUS$161.1Mn/an/an/a3.1×n/a0.0×n/a
Keros Therapeutics, Inc. · NASDAQ:KROSUS$219.7M−US$24.67Mn/a−0.6×n/a0.8×−152.7%0.1×1.16
Immuneering Corporation · NASDAQ:IMRXUS$218.7MUS$160.5Mn/an/an/a1.3×n/a0.0×1.17
Allogene Therapeutics, Inc. · NASDAQ:ALLOUS$217.5M−US$7.44Mn/a−1.6×n/a0.6×n/a0.2×1.93
ProKidney Corp. · NASDAQ:PROKUS$217.3MUS$77.56Mn/a100×n/an/an/an/a1.61
Pyxis Oncology, Inc. · NASDAQ:PYXSUS$216.5MUS$160.9Mn/an/an/a5.2×n/a0.0×0.89
Oryzon Genomics SA · BME:ORYUS$216.4MUS$206.7Mn/an/an/a1.6×n/a0.1×n/a
Rocket Pharmaceuticals, Inc. · NASDAQ:RCKTUS$214.1M−US$25.02Mn/an/an/a0.7×n/a0.1×1.72
Median of the othersUS$218.1MUS$121.4M1.3×1.5×−130.5%0.1×1.17

Forecasts

Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.

Price target
1.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.050 · 1 analyst

Team and board

OfficerRole
Linda F. PowersChief Executive Officer
Alton L. BoyntonChief Scientific Officer
Marnix L. BoschPh.D. Chief Technical Officer

Events

QuarterResultsShare move
Q2 2026Aug 13, 2026 · After close0.0%
Q3 2025Nov 14, 2025 · After close−4.2%
Q2 2025Aug 14, 2025+4.2%
Q1 2025May 8, 2025 · After close+3.7%
Q4 2024Mar 31, 2025−8.7%
Q3 2024Nov 7, 2024 · After close+15.4%
Q2 2024Aug 9, 2024 · After close0.0%
Q1 2024May 10, 2024 · After close0.0%
Q4 2023Mar 5, 2024 · After close+3.6%
Q3 2023Nov 9, 2023 · After close+1.1%
All 20 quarters
QuarterResultsShare move
Q2 2023Aug 9, 2023 · After close+2.0%
Q1 2023May 10, 2023 · After close+3.5%
Q4 2022Feb 28, 2023 · After close0.0%
Q3 2022Nov 9, 2022 · After close+2.9%
Q2 2022Aug 9, 2022 · After close+1.5%
Q1 2022May 19, 2022−1.4%
Q4 2021Mar 2, 2022−6.7%
Quarter to Sep 30, 2021Nov 18, 2021−8.9%
Quarter to Jun 30, 2021Aug 13, 2021−2.4%
Quarter to Mar 31, 2021May 20, 2021+3.2%

Open Events

Decks

DeckKindSlidesDate
Shareholder Meeting (July 2026)Shareholder meeting18 slidesJul 3, 2026
Technical Presentation (June 2025)Technical14 slidesJune 2025
ASCO 2023Conference44 slidesJun 3, 2023
Glioblastoma Drug Development Summit 2023Conference33 slidesMar 15, 2023
Glioblastoma Drug Development Summit 2023Conference33 slidesMar 15, 2023
Technical Presentation (February 2021)Technical30 slidesFebruary 2021
ASCO 2019Conference35 slidesJun 2, 2019
Phacilitate Conference 2019Conference26 slidesJan 23, 2019
I-O Summit 2018Conference21 slidesAug 29, 2018
Investor Presentation (August 2017)Investor deck31 slidesAug 31, 2017
All 15 decks
DeckKindSlidesDate
2nd Immunotherapy of Cancer Conference (ITOC-2) 2015Conference15 slidesMar 30, 2015
Brain Tumor Biotech Summit 2013Conference24 slidesJun 7, 2013
Big CEOs Investor Conference 2013Conference27 slidesFeb 11, 2013
Investor Presentation (January 2013)Investor deck29 slidesJanuary 2013
IPO Roadshow (November 2012)IPO roadshow31 slidesNov 2, 2012

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue1.38M1.38M1.93M1.68M1.00M1.29M2.41M412.0K336.0K623.0K
Research and development28.8M34.9M27.7M35.5M20.3M33.6M14.1M18.2M33.5M60.1M
Operating income-59.9M-66.5M-55.5M-67.2M-52.7M-86.6M-28.0M-41.5M-54.7M-79.3M
Depreciation and amortization2.06M1.74M1.52M1.25M324.0K87.0K21.0K1.29M439.0K189.0K
EBITDA-57.9M-64.8M-54.0M-65.9M-52.4M-86.5M-28.0M-40.2M-54.2M-79.1M
Interest expense8.70M7.77M5.24M6.07M5.01M8.54M2.98M9.87M5.54M3.82M
Income before tax-60.7M-83.8M
Income tax-537.0K000000000
Net income-60.2M-83.8M-62.6M-105.0M179.1M-529.8M-20.8M-35.8M-73.1M-80.2M
Earnings per share, basic-0.04-0.07-0.06-0.100.21-0.73-0.04-0.12-0.31-0.77
Earnings per share, diluted-0.04-0.07-0.06-0.10-0.06-0.73-0.04-0.12-0.31-0.77

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.04M2.17M2.13M6.96M15.2M9.98M372.0K22.2M117.0K6.87M
Current assets5.52M4.06M4.13M9.43M17.3M15.5M3.20M23.8M1.40M7.88M
Property, plant and equipment17.4M16.2M17.3M13.4M15.0M1.04M281.0K108.0K47.5M315.0K
Goodwill626.0K626.0K626.0K626.0K626.0K626.0K0
Total assets81.3M26.7M27.9M31.3M40.2M32.9M10.6M24.7M48.9M52.9M
Accounts payable12.4M
Current liabilities91.7M68.3M45.2M126.0M133.8M382.4M44.2M69.8M87.7M76.4M
Total debt60.0M62.7M40.8M21.5M32.4M14.8M12.7M16.8M31.4M31.7M
Total liabilities128.9M105.7M74.9M136.4M164.2M395.8M55.7M71.8M96.2M79.4M
Shareholders' equity-60.3M-94.5M-65.8M-128.1M-124.0M-362.9M-45.1M-48.1M-67.3M-26.5M
Shares outstanding1.56B1.33B1.18B1.07B948.4M829.6M614.3M523.2M328.9M157.0M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-44.8M-57.0M-53.6M-52.8M-38.3M-32.1M-31.9M-34.6M-36.5M-55.7M
Capital spending-1.50M-1.01M-171.0K
Free cash flow-46.3M-58.0M-32.0M
Cash from investing-1.81M-1.01M-3.44M-2.90M-6.01M-8.14M-360.0K45.4M212.0K-4.94M
Cash from financing49.3M56.8M52.8M42.0M48.1M52.7M9.95M7.87M34.3M38.3M
Change in cash865.0K49.0K-4.84M-8.20M5.19M9.61M-21.9M22.1M-6.75M-16.2M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportOct 30, 2026Material contractSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportJul 31, 2026Material contractSEC
424B5 · ProspectusJul 31, 2026Offer documentSEC
8-K · Current reportJul 17, 2026Current reportSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
EFFECT · Notice that a registration is effectiveApr 21, 2026Other filingsSEC
POS AM · Amendment to an effective registrationApr 16, 2026Offer documentSEC
10-K · Annual reportApr 15, 2026Annual reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportApr 7, 2026Acquisition or disposalSEC
NT 10-K · Late filing noticeMar 31, 2026Explanation requestSEC
8-K · Current reportJan 15, 2026Current reportSEC
8-K · Current reportJan 2, 2026Meeting outcomeSEC
DEF 14A · Proxy statementNov 28, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveNov 26, 2025Other filingsSEC
424B5 · ProspectusNov 25, 2025Offer documentSEC
CORRESP · Letter to the SECNov 24, 2025Other filingsSEC
8-K · Current reportNov 20, 2025Material contractSEC
PRE 14A · Preliminary proxy statementNov 19, 2025Meeting noticeSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
8-K · Current reportOct 31, 2025Material contractSEC
8-K · Current reportOct 30, 2025Material contractSEC
8-K · Current reportOct 24, 2025Current reportSEC
S-3 · Registration statementOct 23, 2025Offer documentSEC
8-K · Current reportOct 14, 2025Current reportSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
424B5 · ProspectusJul 1, 2025Offer documentSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
424B5 · ProspectusDec 26, 2024Offer documentSEC
8-K · Current reportDec 26, 2024Material contractSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 1, 2024Material contractSEC
4 · Change in ownershipSep 3, 2024Insider tradeSEC
4 · Change in ownershipAug 13, 2024Insider tradeSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
8-K · Current reportAug 2, 2024Current reportSEC
4 · Change in ownershipJul 30, 2024Insider tradeSEC
8-K · Current reportJul 3, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialJun 25, 2024Meeting noticeSEC
8-K · Current reportJun 4, 2024Material contractSEC
DEF 14A · Proxy statementJun 3, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementMay 22, 2024Meeting noticeSEC
10-Q · Quarterly reportMay 10, 2024Quarterly reportSEC
8-K · Current reportMay 2, 2024Material contractSEC
10-K/A · Annual report, amendedApr 29, 2024Annual reportSEC
8-K · Current reportMar 22, 2024Management or board changeSEC
8-K · Current reportMar 14, 2024Management or board changeSEC
10-K · Annual reportMar 5, 2024Annual reportSEC
NT 10-K · Late filing noticeMar 1, 2024Explanation requestSEC
4 · Change in ownershipDec 1, 2023Insider tradeSEC
8-K · Current reportNov 16, 2023Material contractSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
10-Q · Quarterly reportAug 9, 2023Quarterly reportSEC
10-Q · Quarterly reportMay 10, 2023Quarterly reportSEC
4 · Change in ownershipApr 5, 2023Insider tradeSEC
4 · Change in ownershipApr 5, 2023Insider tradeSEC
8-K · Current reportMar 8, 2023Material contractSEC
10-K · Annual reportFeb 28, 2023Annual reportSEC
5 · Annual statement of ownershipFeb 7, 2023Insider tradeSEC
8-K · Current reportJan 13, 2023Current reportSEC
8-K · Current reportJan 6, 2023Meeting outcomeSEC
DEFA14A · Additional proxy materialDec 23, 2022Meeting noticeSEC
DEFA14A · Additional proxy materialDec 16, 2022Meeting noticeSEC
4 · Change in ownershipDec 5, 2022Insider tradeSEC
DEF 14A · Proxy statementDec 5, 2022Meeting noticeSEC
PRE 14A · Preliminary proxy statementNov 25, 2022Meeting noticeSEC
10-Q · Quarterly reportNov 9, 2022Quarterly reportSEC
EFFECT · Notice that a registration is effectiveOct 26, 2022Other filingsSEC
CORRESP · Letter to the SECOct 24, 2022Other filingsSEC
UPLOAD · Letter from the SECOct 21, 2022Other filingsSEC
CORRESP · Letter to the SECOct 21, 2022Other filingsSEC
S-3 · Registration statementOct 18, 2022Offer documentSEC
10-Q · Quarterly reportAug 9, 2022Quarterly reportSEC
8-K · Current reportJul 26, 2022Current reportSEC
UPLOAD · Letter from the SECJul 14, 2022Other filingsSEC
10-K/A · Annual report, amendedJun 30, 2022Annual reportSEC
UPLOAD · Letter from the SECJun 28, 2022Other filingsSEC
10-Q · Quarterly reportMay 9, 2022Quarterly reportSEC
10-K/A · Annual report, amendedMay 2, 2022Annual reportSEC
10-K · Annual reportMar 1, 2022Annual reportSEC
8-K · Current reportNov 29, 2021Material contractSEC
10-Q · Quarterly reportNov 15, 2021Quarterly reportSEC
10-Q · Quarterly reportAug 16, 2021Quarterly reportSEC
8-K · Current reportMay 24, 2021Meeting outcomeSEC
10-Q · Quarterly reportMay 17, 2021Quarterly reportSEC
DEF 14A · Proxy statementApr 16, 2021Meeting noticeSEC
10-K · Annual reportMar 31, 2021Annual reportSEC
8-K · Current reportMar 5, 2021Material contractSEC
8-K · Current reportJan 26, 2021Current reportSEC
4 · Change in ownershipJan 19, 2021Insider tradeSEC
10-Q · Quarterly reportJan 15, 2021Quarterly reportSEC
NT 10-Q · Late filing noticeNov 10, 2020Explanation requestSEC
8-K · Current reportNov 2, 2020Current reportSEC
4 · Change in ownershipOct 16, 2020Insider tradeSEC
424B5 · ProspectusOct 13, 2020Offer documentSEC
8-K/A · Current report, amendedSep 15, 2020Meeting outcomeSEC
DSep 14, 2020Other filingsSEC
8-K · Current reportSep 1, 2020Acquisition or disposalSEC
8-K · Current reportAug 20, 2020Material contractSEC
10-Q · Quarterly reportAug 10, 2020Quarterly reportSEC
424B5 · ProspectusAug 7, 2020Offer documentSEC
4 · Change in ownershipJul 2, 2020Insider tradeSEC
4 · Change in ownershipJul 2, 2020Insider tradeSEC
4 · Change in ownershipJul 2, 2020Insider tradeSEC
4 · Change in ownershipJul 2, 2020Insider tradeSEC
4 · Change in ownershipJul 2, 2020Insider tradeSEC
4 · Change in ownershipJul 2, 2020Insider tradeSEC
4 · Change in ownershipJul 2, 2020Insider tradeSEC
4 · Change in ownershipJul 2, 2020Insider tradeSEC
4 · Change in ownershipJul 2, 2020Insider tradeSEC
424B5 · ProspectusJun 26, 2020Offer documentSEC
10-Q · Quarterly reportJun 23, 2020Quarterly reportSEC
10-K/A · Annual report, amendedJun 23, 2020Annual reportSEC
424B5 · ProspectusJun 12, 2020Offer documentSEC
8-K · Current reportJun 8, 2020Management or board changeSEC
8-K · Current reportJun 4, 2020Management or board changeSEC
424B5 · ProspectusMay 29, 2020Offer documentSEC
8-K · Current reportMay 27, 2020Material contractSEC
8-K · Current reportMay 20, 2020Current reportSEC
NT 10-Q · Late filing noticeMay 12, 2020Explanation requestSEC
4 · Change in ownershipMay 1, 2020Insider tradeSEC
8-K · Current reportApr 23, 2020Meeting outcomeSEC
424B5 · ProspectusApr 9, 2020Offer documentSEC
8-K · Current reportApr 1, 2020Material contractSEC
DEF 14A · Proxy statementMar 27, 2020Meeting noticeSEC
10-K · Annual reportMar 16, 2020Annual reportSEC
424B5 · ProspectusFeb 24, 2020Offer documentSEC
4 · Change in ownershipFeb 5, 2020Insider tradeSEC
424B5 · ProspectusJan 15, 2020Offer documentSEC
424B5 · ProspectusJan 3, 2020Offer documentSEC
3 · Initial statement of ownershipDec 20, 2019Insider tradeSEC
8-K · Current reportDec 13, 2019Management or board changeSEC
10-Q · Quarterly reportNov 12, 2019Quarterly reportSEC
EFFECT · Notice that a registration is effectiveNov 1, 2019Other filingsSEC
CORRESP · Letter to the SECOct 29, 2019Other filingsSEC
424B5 · ProspectusOct 28, 2019Offer documentSEC
UPLOAD · Letter from the SECOct 28, 2019Other filingsSEC
424B5 · ProspectusOct 18, 2019Offer documentSEC
S-3 · Registration statementOct 18, 2019Offer documentSEC
10-Q · Quarterly reportAug 9, 2019Quarterly reportSEC
8-K · Current reportJul 22, 2019FinancingSEC
424B5 · ProspectusJul 17, 2019Offer documentSEC
424B5 · ProspectusJul 17, 2019Offer documentSEC
8-K · Current reportMay 28, 2019Material contractSEC
10-Q · Quarterly reportMay 10, 2019Quarterly reportSEC
10-K · Annual reportApr 2, 2019Annual reportSEC
NT 10-K · Late filing noticeMar 19, 2019Explanation requestSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2019Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2019Big-stake noticeSEC
8-K · Current reportFeb 7, 2019Meeting outcomeSEC
4 · Change in ownershipJan 29, 2019Insider tradeSEC
DEF 14A · Proxy statementJan 7, 2019Meeting noticeSEC
8-K · Current reportDec 20, 2018Acquisition or disposalSEC
8-K · Current reportDec 11, 2018Material contractSEC
8-K · Current reportNov 28, 2018Current reportSEC
8-K · Current reportNov 23, 2018Management or board changeSEC
10-Q · Quarterly reportNov 16, 2018Quarterly reportSEC
NT 10-Q · Late filing noticeNov 15, 2018Explanation requestSEC
8-K · Current reportNov 13, 2018Material contractSEC
8-K · Current reportSep 13, 2018FinancingSEC
10-Q · Quarterly reportAug 14, 2018Quarterly reportSEC
8-K · Current reportJun 28, 2018Current reportSEC
424B5 · ProspectusJun 28, 2018Offer documentSEC
4 · Change in ownershipJun 18, 2018Insider tradeSEC
8-K · Current reportJun 18, 2018FinancingSEC
8-K · Current reportJun 1, 2018Management or board changeSEC
8-K · Current reportMay 31, 2018FinancingSEC
4 · Change in ownershipMay 31, 2018Insider tradeSEC
4 · Change in ownershipMay 30, 2018Insider tradeSEC
4 · Change in ownershipMay 30, 2018Insider tradeSEC
4 · Change in ownershipMay 30, 2018Insider tradeSEC
4 · Change in ownershipMay 30, 2018Insider tradeSEC
8-K · Current reportMay 21, 2018FinancingSEC
10-Q · Quarterly reportMay 16, 2018Quarterly reportSEC
NT 10-Q · Late filing noticeMay 16, 2018Explanation requestSEC
8-K · Current reportMay 7, 2018Material contractSEC
8-K · Current reportMay 2, 2018Meeting outcomeSEC
10-K · Annual reportApr 17, 2018Annual reportSEC
DEFR14AApr 12, 2018Meeting noticeSEC
DEF 14A · Proxy statementApr 9, 2018Meeting noticeSEC
UPLOAD · Letter from the SECApr 6, 2018Other filingsSEC
CORRESP · Letter to the SECApr 4, 2018Other filingsSEC
PRER14AApr 4, 2018Other filingsSEC
NT 10-K · Late filing noticeApr 2, 2018Explanation requestSEC
UPLOAD · Letter from the SECApr 2, 2018Other filingsSEC
424B5 · ProspectusMar 26, 2018Offer documentSEC
PRE 14A · Preliminary proxy statementMar 26, 2018Meeting noticeSEC
4/A · Change in ownership, amendedMar 22, 2018Insider tradeSEC
8-K · Current reportMar 22, 2018Current reportSEC
4 · Change in ownershipMar 21, 2018Insider tradeSEC
8-K · Current reportMar 20, 2018Material contractSEC
8-K · Current reportMar 15, 2018FinancingSEC
4 · Change in ownershipMar 14, 2018Insider tradeSEC
8-K · Current reportMar 7, 2018FinancingSEC
8-K · Current reportMar 2, 2018Management or board changeSEC
8-K · Current reportFeb 21, 2018FinancingSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2018Big-stake noticeSEC

This page holds 200 of 804 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Northwest Biotherapeutics, Inc.’s releases

Common shares
1,705,637,993
Fully diluted
1,705,637,993

Fully diluted

LineShares
Common shares1,705,637,993

Share count over time

CountShares
Nov 22, 20261,705,637,993

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Compass Financial Management LLC1.63M0.09%US$243KSep 30, 2026
Opus Capital Group, LLC60,150<0.01%US$9Sep 30, 2026
Ethos Financial Group, LLC39,070<0.01%US$5,818Sep 30, 2026
Williams Jones Wealth Management, LLC.25,000<0.01%US$3,723Sep 30, 2026
Markowski Investments1,050<0.01%US$156Sep 30, 2026
Hantz Financial Services, Inc.250<0.01%Sep 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Susan B Bayh
Other companies: Dendreon Corp (Director · Dec 6, 2006 – Jan 3, 2014 · Past); Curis, Inc. (Director · Jun 1, 2006 – Jan 17, 2013 · Past); Dyax Corp (Director · May 18, 2006 – May 6, 2010 · Past); Elevance Health, Inc. (Director · Feb 3, 2006 – May 21, 2012 · Past)
Director · Jan 25, 2016 – Jan 25, 2016 · Past
Jerry J Jasinowski
Other companies: Timken Company (the) (Director · Feb 6, 2006 – May 11, 2010 · Past); Webmethods Inc (Director · Jan 3, 2006 – May 29, 2007 · Past); The Phoenix Companies Inc (Director · Oct 3, 2005 – Apr 1, 2009 · Past)
Director · Apr 30, 2015 – Dec 1, 2022 · Past
Alton L. BoyntonChief Scientific Officer · Since at least May 17, 2006
Anthony P DeaseySenior VP of Finance - CFO, Director · Oct 1, 2007 – Oct 1, 2007 · Past
Cofer BlackDirector · May 28, 2018 – May 28, 2018 · Past
Jean M DavisSee Remarks · Dec 9, 2019 – Dec 9, 2019 · Past
Leslie J GoldmanSee Remarks · Jul 2, 2020 – Jul 2, 2020 · Past
Linda F. PowersChief Executive Officer · Since at least Oct 8, 2026
Marnix L. BoschPh.D. Chief Technical Officer · Since at least Apr 3, 2023
Robert A FarmerDirector · Apr 30, 2015 – Apr 30, 2015 · Past

Open People

Log in to ask 6ix AI your own questions about Northwest Biotherapeutics, Inc.